Details

Title

Outcomes of Jehovah’s Witnesses with hematological malignancies treated without transfusions — single center experience

Journal title

Folia Medica Cracoviensia

Yearbook

2020

Volume

Vol. 60

Issue

No 4

Affiliation

Drozd-Sokołowska, Joanna Ewa : Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Poland ; Waszczuk-Gajda, Anna : Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Poland ; Dwilewicz-Trojaczek, Jadwiga : Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Poland ; Walesiak, Alicja : Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Poland ; Krzyżanowska, Monika : Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Poland ; Paluszewska, Monika : Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Poland ; Wieczorek, Jolanta : Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Poland ; Wiktor-Jędrzejczak, Wiesław : Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Poland

Authors

Keywords

Jehovah’s Witnesses ; leukemia ; lymphoma ; blood transfusion ; platelet transfusion

Divisions of PAS

Nauki Medyczne

Coverage

53-64

Bibliography

1. Bouchnita A., Eymard N., Moyo T.K., Koury M.J., Volpert V.: Bone marrow infiltration by multiple myeloma causes anemia by reversible disruption of erythropoiesis. Am J Hematol. 2016; 91 (4): 371– 378. doi: 10.1002/ajh.24291.
2. Wang Y., Gao A., Zhao H., et al.: Leukemia cell infiltration causes defective erythropoiesis partially through MIP-1alpha/CCL3. Leukemia. 2016; 30 (9): 1897–1908. doi: 10.1038/leu.2016.81.
3. Bohlius J., Bohlke K., Castelli R., et al.: Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update. J Clin Oncol. 2019; 37 (15): 1336–1351. doi: 10.1200/JCO.18.02142.
4. Schiffer C.A., Bohlke K., Delaney M., et al.: Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2018; 36 (3): 283–299. doi: 10.1200/JCO.2017.76.1734.
5. Drozd-Sokolowska J.E., Wiktor-Jedrzejczak W.: Factors determining the risk of severe (WHO grades 3 and 4) hemorrhage in hematologic patients. Transfus Apher Sci. 2011; 44: 129–134. doi: 10.1016/j. transci.2011.01.004.
6. Rodgers G.M., Gilreath J.A., Alwan L., et al.: Cancer- and Chemotherapy Induced Anemia. NCCN Clinical Practice Guidelines in Oncology. https://www.nccn.org/professionals/physician_gls/f_guidelines. asp#anemia: NCCN; 2016.
7. Laszlo D., Agazzi A., Goldhirsch A., et al.: Tailored therapy of adult acute leukaemia in Jehovah’s Witnesses: unjustified reluctance to treat. Eur J Haematol. 2004; 72 (4): 264–267. doi: 10.1111/ j.0902-4441.2003.00211.x.
8. Chojnowski K., Janus A., Blizniewska K., Robak M., Trelinski J.: Long-lasting extreme anemia during the therapy of acute lymphoblastic leukemia in a Jehovah’s Witness patient. Transfusion. 2016; 56 (10): 2438–2442. doi: 10.1111/trf.13703.
9. Mazza P., Palazzo G., Amurri B., Cervellera M., Rizzo C., Maggi A.: Acute leukemia in Jehovah’s Witnesses: a challenge for hematologists. Haematologica. 2000; 85: 1221–1222.
10. Brown N.M., Keck G., Ford P.A.: Acute myeloid leukemia in Jehovah Witnesses. Leuk Lymphoma. 2008; 49 (4): 817–820. doi: 10.1080/10428190801911670.
11. Cullis J.O., Duncombe A.S., Dudley J.M., Lumley H.S., Apperley J.F., Smith A.G.: Acute leukaemia in Jehovah’s Witnesses. Br J Haematol. 1998; 100 (4): 664–668. doi: 10.1046/j.1365-2141.1998.00634.x.
12. Wilop S., Osieka R.: Antineoplastic chemotherapy in Jehovah’s Witness patients with acute myelogenous leukemia refusing blood products — a matched pair analysis. Hematology. 2018; 23 (6): 324–329. doi: 10.1080/10245332.2017.
13. Ford P.A., Grant S.J., Mick R., Keck G.: Autologous Stem-Cell Transplantation Without Hematopoietic Support for the Treatment of Hematologic Malignancies in Jehovah’s Witnesses. J Clin Oncol. 2015; 33 (15): 1674–1679. doi: 10.1200/JCO.2014.57.9912.
14. Agapidou A., Vakalopoulou S., Papadopoulou T., Chadjiaggelidou C., Garypidou V.: Successful Treatment of Severe Anemia using Erythropoietin in a Jehovah Witness with Non-Hodgkin Lymphoma. Hematol Rep. 2014; 6 (4): 5600. doi: 10.4081/hr.2014.5600.
15. Yamamoto Y., Kawashima A., Kashiwagi E., Ogata K.: A Jehovah’s Witness with Acute Myeloid Leukemia Successfully Treated with an Epigenetic Drug, Azacitidine: A Clue for Development of Anti-AML Therapy Requiring Minimum Blood Transfusions. Case Rep Hematol. 2014; 2014: 141260. doi: 10.1155/2014/141260.
16. Garelius H., Grund S., Stockelberg D.: Induction with azacytidine followed by allogeneic hematopoietic stem cell transplantation in a Jehovah’s Witness with acute monocytic leukemia. Clin Case Rep. 2015; 3 (5): 287–290. doi: 10.1002/ccr3.212.
17. Bareford D., Odeh B., Narayanan S., Wiltshire S.: Remission induction in a Jehovah’s witness patient with acute myeloid leukaemia using gemtuzumab ozogamicin. Transfus Med. 2005; 15 (5): 445–448. doi: 10.1111/j.1365-3148.2005.00611.x.
18. Fujisawa S., Naito K., Matsuoka T., Kobayashi M.: Complete remission induced by gemtuzumab ozogamicin in a Jehovah’s Witness patient with acute myelogenous leukemia. Int J Hematol. 2007; 85 (5): 418–420. doi: 10.1532/IJH97.07018.
19. Donahue L.L., Shapira I., Shander A., Kolitz J., Allen S., Greenburg G.: Management of acute anemia in a Jehovah’s Witness patient with acute lymphoblastic leukemia with polymerized bovine hemoglobin- based oxygen carrier: a case report and review of literature. Transfusion. 2010; 50 (7): 1561– 1567. doi: 10.1111/j.1537-2995.2010.02603.x.

Date

2021.04.08

Type

Article

Identifier

DOI: 10.24425/fmc.2020.136204

Source

Folia Medica Cracoviensia; 2020; Vol. 60; No 4; 53-64
×